On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.

On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.